← FDA DRUG APPROVALS

FDA NDA · NDA219407

DAWNZERA

donidalorsen

Sponsor: IONIS PHARMS INC

APPLICATION
NDA219407
TYPE
NDA
ORIGINAL APPROVAL
2025-08-21
LATEST ACTION
2025-08-21
ROUTE
SUBCUTANEOUS
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

DAWNZERA (AUTOINJECTOR) · ReferencePrescription
DONIDALORSEN SODIUM EQ 80MG BASE/0.8ML (EQ 80MG BASE/0.8ML) · SOLUTION · SUBCUTANEOUS

Approval history

2025-08-21Type 1 - New Molecular Entity · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →